Compare Kroger Co (KR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Sanofi SA — how do they compare? Kroger Co trades at $57.72 (market cap $35.75B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 2.9× Kroger Co's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| KR | SNY | |
|---|---|---|
Market Cap | $35.75B | $104.83B |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $52.34 |
52-Week Low | $55.53 | $41.33 |
Enterprise Value | $55.85B | $121.32B |
Dividend Yield | 2.47% | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $57.78, down 1.77% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a low P/S ratio of 0.25 and improving cash flow, generating $2.08B net cash in 2025. Recent developments include the $1.65B Giant Eagle acquisition expanding Midwest presence and ongoing dividend payments, with analyst consensus pointing to 19% upside to the $68.63 price target.
KR presents a value opportunity with defensive characteristics, trading below analyst targets amid competitive grocery sector pressures. Key risks include margin compression from industry pricing wars and integration challenges from recent acquisitions, while positive catalysts include retail media growth and private label expansion driving long-term shareholder value.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
